Clinical Trials Browser

Has results × Neoplasms × durvalumab × Clear all

Neoplasms, Hematologic Neoplasms

NCT03822351 2024-10-08

COAST

Phase 2 Completed

189 enrolled 24 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT03439085 2024-07-09

DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers

Phase 2 Terminated

41 enrolled 13 charts

GastrointestinalGenitourinaryGynecologic

Anal Canal Carcinoma, Anus Neoplasms, Uterine Cervical Neoplasms, Neoplasm Metastasis, Neoplasms, Penile Neoplasms, Recurrence, Vaginal Neoplasms, Vulvar Neoplasms

NCT03094286 2024-06-24

Durvalumab in HIV-1 Patients With Solid Tumors

Phase 2 Completed

20 enrolled 36 charts

Tumor-Agnostic

Neoplasms

NCT03206073 2023-10-24

A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer

Phase 1/2 Completed

34 enrolled 18 charts

Gastrointestinal

Neoplasms, Colorectal Neoplasms

NCT02904954 2023-10-11

Durvalumab (MEDI4736) With or Without SBRT in Clinical Stage I, II and IIIA Non-small Cell Lung Cancer

Phase 2 Completed

60 enrolled 12 charts

Thoracic

Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms, Neoplasms by Site, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT02291055 2023-03-20

A Study of ADXS11-001 or MEDI4736 Alone or Combination In Cervical or Human Papillomavirus (HPV)+ Head & Neck Cancer

Phase 1/2 Terminated

75 enrolled 23 charts

GynecologicHead & Neck

Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms

NCT03162224 2022-08-25

Safety and Efficacy of MEDI0457 and Durvalumab in Participants With Human Papilloma Virus (HPV) Associated Recurrent/Metastatic Head and Neck Cancer

Phase 1/2 Completed

35 enrolled 25 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Neoplasm Metastasis, Neoplasms, Oropharyngeal Neoplasms, Recurrence

NCT03794544 2022-02-24

Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer

Phase 2 Completed

84 enrolled 17 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms

Clinical Trials

Durvalumab and Tremelimumab for Pediatric Malignancies

COAST

DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers

Durvalumab in HIV-1 Patients With Solid Tumors

A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer

Durvalumab (MEDI4736) With or Without SBRT in Clinical Stage I, II and IIIA Non-small Cell Lung Cancer

A Study of ADXS11-001 or MEDI4736 Alone or Combination In Cervical or Human Papillomavirus (HPV)+ Head & Neck Cancer

Safety and Efficacy of MEDI0457 and Durvalumab in Participants With Human Papilloma Virus (HPV) Associated Recurrent/Metastatic Head and Neck Cancer

Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer